Fabry Disesase clinical trials at University of California Health

1 research study open to eligible people

Showing trials for

  • HM15421/GC1134A in Patients With Fabry Disease

    open to eligible people ages 18 years and up

    This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.

    at UCLA

Last updated: